These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 8521771)
1. Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Brogden RN; McTavish D Drugs; 1995 Sep; 50(3):495-512. PubMed ID: 8521771 [TBL] [Abstract][Full Text] [Related]
2. P&T Committee review of nifedipine GITS: new modality for angina and hypertension. Weintraub M; Horn J; Krakoff L; Vetrovec G Hosp Formul; 1990 Mar; 25 Suppl A():10-4. PubMed ID: 10103975 [TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of nifedipine gastrointestinal therapeutic system versus diltiazem when added to beta blockers in stable angina pectoris. Siu SC; Jacoby RM; Phillips RT; Nesto RW Am J Cardiol; 1993 Apr; 71(11):887-92. PubMed ID: 8096670 [TBL] [Abstract][Full Text] [Related]
4. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Grundy JS; Foster RT Clin Pharmacokinet; 1996 Jan; 30(1):28-51. PubMed ID: 8846626 [TBL] [Abstract][Full Text] [Related]
5. Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris. Croom KF; Wellington K Drugs; 2006; 66(4):497-528. PubMed ID: 16597165 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension. Fagan TC; Haggert BE; Liss C Clin Ther; 1994; 16(4):634-46. PubMed ID: 7982251 [TBL] [Abstract][Full Text] [Related]
7. Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders. Murdoch D; Brogden RN Drugs; 1991 May; 41(5):737-79. PubMed ID: 1712708 [TBL] [Abstract][Full Text] [Related]
8. Once daily nifedipine: the formulation dictates the pharmacokinetic characteristics and the therapeutic responses. Toal CB; Meredith PA; Elliott HL Int J Clin Pharmacol Ther; 2012 Mar; 50(3):202-17. PubMed ID: 22373833 [TBL] [Abstract][Full Text] [Related]
9. Innovative drug delivery systems in cardiovascular medicine: nifedipine-GITS and clonidine-TTS. Frishman WH; Sherman D; Feinfeld DA Cardiol Clin; 1987 Nov; 5(4):703-16. PubMed ID: 3331321 [TBL] [Abstract][Full Text] [Related]
10. Early experience with dobutamine stress testing and cardiac cine-tomographic imaging in the elderly: antianginal effects of nifedipine-GITS. Schwartz JB; Caputo G; Abbott J J Am Geriatr Soc; 1993 Sep; 41(9):967-74. PubMed ID: 8409183 [TBL] [Abstract][Full Text] [Related]
12. Monotherapy with nifedipine GITS compared with atenolol in stable angina pectoris. The Working Group on Cardiovascular Research (WCN). de Vries RJ; Dunselman PH Br J Clin Pract Suppl; 1997 Apr; 88():6-9. PubMed ID: 9519501 [TBL] [Abstract][Full Text] [Related]
13. Once-daily therapy for angina pectoris with nifedipine gastrointestinal therapeutic system. Dosing and clinical efficacy. Vetrovec GW Am J Med; 1989 Jan; 86(1A):28-32. PubMed ID: 2644830 [TBL] [Abstract][Full Text] [Related]
14. Nifedipine gastrointestinal therapeutic system in stable angina pectoris. Results of a multicenter open-label crossover comparison with standard nifedipine. Vetrovec GW; Parker VE; Cole S; Procacci PM; Tabatznik B; Terry R Am J Med; 1987 Dec; 83(6B):24-9. PubMed ID: 3140660 [TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of once-daily nifedipine: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate diastolic hypertension. Nifedipine Study Group. Glasser SP; Jain A; Allenby KS; Shannon T; Pride K; Pettis PP; Schwartz LA; MacCarthy EP Clin Ther; 1995; 17(1):12-29. PubMed ID: 7758054 [TBL] [Abstract][Full Text] [Related]
16. Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Friedel HA; Sorkin EM Drugs; 1988 Dec; 36(6):682-731. PubMed ID: 3065058 [TBL] [Abstract][Full Text] [Related]
17. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris. Brogden RN; Markham A Drugs; 1997 Nov; 54(5):774-93. PubMed ID: 9360062 [TBL] [Abstract][Full Text] [Related]
18. Conversion from sustained-release to immediate-release calcium entry blockers: outcome in patients with mild-to-moderate hypertension. Hilleman DE; Mohiuddin SM; Lucas BD; Shinn B; Elsasser GN Clin Ther; 1993; 15(6):1002-10. PubMed ID: 8111798 [TBL] [Abstract][Full Text] [Related]
19. Medical therapy, symptoms, and the distress the cause: relation to quality of life in patients with angina pectoris and/or hypertension. Hollenberg NK; Williams GH; Anderson R Arch Intern Med; 2000 May; 160(10):1477-83. PubMed ID: 10826461 [TBL] [Abstract][Full Text] [Related]
20. [Pharmacology and clinical use of a fixed combination of nifedipine and slow release atenolol (Niften) in the treatment of arterial hypertension and angina pectoris]. Verdecchia P Minerva Cardioangiol; 1993 Sep; 41(9):349-63. PubMed ID: 7903118 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]